User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice: A multi-country, questionnaire-based study

Clinical Drug Investigation

Volumn 29, Issue 3, 2009, Pages 153-159

  Short, Mary ^a  

^a Rock Court Medical Centre ^*  (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; YASMINELLE;

ACNE; ADULT; ALLOPATHY; ARTICLE; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFECT; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; PATIENT ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; WATER RETENTION; WEIGHT REDUCTION;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DRUG COMBINATIONS; DRUG ERUPTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; IRELAND; MENSTRUATION; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; QUESTIONNAIRES; WEIGHT GAIN; YOUNG ADULT;

EID: 61349151087     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929030-00002     Document Type: Article

References (27)

1. Shvarts S, Besinque K, Atkinson R, et al. New advances in contraception. Insights 2002: 11-22
2. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al., editors. Contraceptive technology. New York: Ardent Media, 2004: 355-63
3. Kaunitz AM. Combined oral contraception with desogestrel/ethinyl estradiol: tolerability profile. Am J Obstet Gynecol 1993; 168: 1028-33
4. Bagshaw S. The combined oral contraceptive: risks and adverse effects in perspective. Drug Saf 1995; 12: 91-6
5. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283-8
6. Fuchs N, Prinz H, Koch U. Attitudes to current oral contraceptive use and future developments: the women's perspective. Eur J Contracept Reprod Health Care 1996; 1: 275-84
7. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82
8. Cibula D, Karck U, Weidenhammer HG, et al. Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 μg and drospirenone 3 mg. Clin Drug Investig 2006; 26: 143-50
9. Gruber DM, Huber JC, Melis GB, et al. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 μg and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 μg and desogestrel 150 μg. Treat Endocrinol 2006; 5: 115-21
10. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99-10
11. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243-51
12. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38
13. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69: 2-15
14. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74: 123-30
15. Lucky AW, Koltun W, Thiboutot D, et al. 3 mg drospirenone/20 μg EE 24/4 in the treatment of acne vulgaris: lesion counts, subject self-assessment. Cutis 2008; 82: 143-50
16. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 μg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249-56
17. Maloney JM, Dietze P, Watson D, et al. A randomized controlled trial of 3 mg drospirenone/20 μg EE 24/4 COC in the treatment of acne vulgaris. Obstet Gynecol 2008; 112: 773-81
18. Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30 mug and drospirenone 3 mg (Yasmin®) in clinical practice. Treat Endocrinol 2006; 5: 251-6
19. Skouby SO. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries. Eur J Contracept Reprod Health Care 2004; 9: 57-68
20. Gallo MF, Nanda K, Grimes DA, et al. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; (2): CD003989
21. Gallo MF, Nanda K, Grimes DA, et al. Twenty micrograms versus >20 micrograms estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005; 71: 162-9
22. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561-9
23. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002; 47: 14-22
24. Borenstein J, Yu HT, Wade S, et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003; 48: 79-85
25. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72: 414-21
26. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet and Gynecol 2005; 106: 492-501
27. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; (1): CD003987